In:
Kidney360, Ovid Technologies (Wolters Kluwer Health), Vol. 2, No. 4 ( 2021-04), p. 666-673
Abstract:
Citric acid–containing dialysate for hemodialysis was prescribed to 20%–25% of patients in Japanese, Italian, and Belgium centers in the Dialysis Outcomes and Practice Patterns Study. The use of citric acid–containing bicarbonate-based dialysate was not associated with mortality in the international Dialysis Outcomes and Practice Patterns Study cohort. Background Metabolic acidosis is a common threat for patients on hemodialysis, managed by alkaline dialysate. The main base is bicarbonate, to which small amounts of acetic, citric, or hydrochloric acid are added. The first two are metabolized to bicarbonate, mostly by the liver. Citric acid–containing dialysate might improve dialysis efficiency, anticoagulation, calcification propensity score, and intradialytic hemodynamic stability. However, a recent report from the French dialysis registry suggested this dialysate increases mortality risk. This prompted us to assess whether citric acid–containing bicarbonate-based dialysate was associated with mortality in the international Dialysis Outcomes and Practice Patterns Study (DOPPS). Methods Detailed patient-based information on dialysate composition was collected in DOPPS phases 5 and 6 (2012–2017). Cox regression was used to model the association between baseline bicarbonate dialysate containing citric acid versus not containing citric acid and mortality among DOPPS countries and phases where citric acid–containing dialysate was used. Results Citric acid-containing dialysate was most commonly used in Japan, Italy, and Belgium (25%, 25%, 21% and of patients who were DOPPS phase 6, respectively) and used in 〈 10% of patients in other countries. Among 11,306 patients in DOPPS country and phases with at least 15 patients using citric acid-containing dialysate, patient demographics, comorbidities, and laboratories were similar among patients using (14%) versus not using (86%) citric acid-containing dialysate. After accounting for case mix, we did not observe a directional association between citric acid–containing dialysate use (any versus none) and mortality (HR, 1.14; 95% CI, 0.97 to 1.34), nor did we find evidence of a dose-dependent relationship when parameterizing the citric acid concentration in the dialysate as 1, 2, and 3+ mEq/L. Conclusions The use of citric acid–containing dialysate was not associated with greater risk of all-cause mortality in patients on hemodialysis participating in DOPPS. Clinical indications for the use of citric acid–containing dialysate deserve further investigation.
Type of Medium:
Online Resource
ISSN:
2641-7650
DOI:
10.34067/KID.0006182020
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2021
Permalink
